Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers

Publication date: 1 July 2018
Source:Talanta, Volume 184
Author(s): Ana García-Blanco, Carmen Peña-Bautista, Camille Oger, Claire Vigor, Jean-Marie Galano, Thierry Durand, Nuria Martín-Ibáñez, Miguel Baquero, Máximo Vento, Consuelo Cháfer-Pericás
Lipid peroxidation plays an important role in Alzheimer Disease, so corresponding metabolites found in urine samples could be potential biomarkers. The aim of this work is to develop a reliable ultra-performance liquid chromatography-tandem mass spectrometry analytical method to determine a new set of lipid peroxidation compounds in urine samples.Excellent sensitivity was achieved with limits of detection between 0.08 and 17 nmol L⁻¹, which renders this method suitable to monitor analytes concentrations in real samples. The method's precision was satisfactory with coefficients of variation around 5–17% (intra-day) and 8–19% (inter-day). The accuracy of the method was assessed by analysis of spiked urine samples obtaining recoveries between 70% and 120% for most of the analytes. The utility of the described method was tested by analyzing urine samples from patients early diagnosed with mild cognitive impairment or mild dementia Alzheimer Disease following the clinical standard criteria. As preliminary results, some analytes (17(RS)−10-epi-SC-Δ¹⁵−11-dihomo-IsoF, PGE2) and total parameters (Neuroprostanes, Isoprostanes, Isofurans) show differences between the control and the clinical groups. So, these analytes could be potential early Alzheimer Disease biomarkers assessing the patients' pro-oxidant condition.

Graphical abstract

https://ift.tt/2GWzbI3